

RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical
Information Center (STIC) no errors detected.

Application Serial Number: 10/086,177C
Source: 1 Fw/b
Date Processed by STIC: 10/19/06

ENTERED



IFW16

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:36

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

*see
pg 6-7*

3 <110> APPLICANT: Tudan, Christopher R.
 4 Merzouk, Ahmed
 5 Arab, Lakhdar
 6 Saxena, Geeta
 7 Eaves, Connie J.
 8 Cashman, Johanne
 9 Clark-Lewis, Ian
 10 Salari, Hassan
 11 University of British Columbia
 12 Chemokine Therapeutics Corporation
 14 <120> TITLE OF INVENTION: CXC Chemokine Receptor 4 Agonist Peptides
 16 <130> FILE REFERENCE: 080421-000100US
 18 <140> CURRENT APPLICATION NUMBER: US 10/086,177C
 19 <141> CURRENT FILING DATE: 2002-02-26
 21 <150> PRIOR APPLICATION NUMBER: CA 2,305,036
 22 <151> PRIOR FILING DATE: 2000-04-12
 24 <150> PRIOR APPLICATION NUMBER: US 60/232,425
 25 <151> PRIOR FILING DATE: 2000-09-14
 27 <150> PRIOR APPLICATION NUMBER: CA 2,335,109
 28 <151> PRIOR FILING DATE: 2001-02-23
 30 <150> PRIOR APPLICATION NUMBER: US 09/835,107
 31 <151> PRIOR FILING DATE: 2001-04-12
 33 <160> NUMBER OF SEQ ID NOS: 214
 35 <170> SOFTWARE: PatentIn version 3.3
 37 <210> SEQ ID NO: 1
 38 <211> LENGTH: 67
 39 <212> TYPE: PRT
 40 <213> ORGANISM: Homo sapiens
 42 <220> FEATURE:
 43 <223> OTHER INFORMATION: human SDF-1alpha
 45 <400> SEQUENCE: 1
 46 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
 47 1 5 10 15
 48 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
 49 20 25 30
 50 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
 51 35 40 45
 52 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
 53 50 55 60
 54 Ala Leu Asn
 55 65
 57 <210> SEQ ID NO: 2
 58 <211> LENGTH: 93

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:36

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

```

59 <212> TYPE: PRT
60 <213> ORGANISM: Homo sapiens
62 <220> FEATURE:
63 <223> OTHER INFORMATION: human SDF-1 precursor, PBSF
65 <400> SEQUENCE: 2
66 Met Asn Ala Lys Val Val Val Val Leu Val Leu Val Leu Thr Ala Leu
67 1          5          10          15
68 Cys Leu Ser Asp Gly Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys
69          20          25          30
70 Arg Phe Phe Glu Ser His Val Ala Arg Ala Asn Val Lys His Leu Lys
71          35          40          45
72 Ile Leu Asn Thr Pro Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys
73          50          55          60
74 Asn Asn Asn Arg Gln Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln
75 65          70          75          80
76 Glu Tyr Leu Glu Lys Ala Leu Asn Lys Arg Phe Lys Met
77          85          90
79 <210> SEQ ID NO: 3
80 <211> LENGTH: 93
81 <212> TYPE: PRT
82 <213> ORGANISM: Homo sapiens
84 <220> FEATURE:
85 <223> OTHER INFORMATION: human SDF-1beta
87 <400> SEQUENCE: 3
88 Met Asn Ala Lys Val Val Val Val Leu Val Leu Val Leu Thr Ala Leu
89 1          5          10          15
90 Cys Leu Ser Asp Gly Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys
91          20          25          30
92 Arg Phe Phe Glu Ser His Val Ala Arg Ala Asn Val Lys His Leu Lys
93          35          40          45
94 Ile Leu Asn Thr Pro Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys
95          50          55          60
96 Asn Asn Asn Arg Gln Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln
97 65          70          75          80
98 Glu Tyr Leu Glu Lys Ala Leu Asn Lys Arg Phe Lys Met
99          85          90
101 <210> SEQ ID NO: 4
102 <211> LENGTH: 17
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: synthetic CXCR4 agonist SDF-1(1-17), CTCE9902
109 <400> SEQUENCE: 4
110 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
111 1          5          10          15
112 His
115 <210> SEQ ID NO: 5
116 <211> LENGTH: 6
117 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:36

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

```

118 <213> ORGANISM: Artificial Sequence
120 <220> FEATURE:
121 <223> OTHER INFORMATION: CXCR4 agonist sequence motif within 20 amino acids
122     of the N-terminus
124 <400> SEQUENCE: 5
125 Arg Phe Phe Glu Ser His
126 1         5
128 <210> SEQ ID NO: 6
129 <211> LENGTH: 9
130 <212> TYPE: PRT
131 <213> ORGANISM: Artificial Sequence
133 <220> FEATURE:
134 <223> OTHER INFORMATION: synthetic SDF-1 peptide analogue CXCR4 agonist
136 <400> SEQUENCE: 6
137 Lys Pro Val Ser Leu Ser Tyr Arg Cys
138 1         5
140 <210> SEQ ID NO: 7
141 <211> LENGTH: 9
142 <212> TYPE: PRT
143 <213> ORGANISM: Artificial Sequence
145 <220> FEATURE:
146 <223> OTHER INFORMATION: synthetic CXCR4 agonist SDF-1(1-9)-2-C9/C9-cysteine dimer,
147     CTCE9901
149 <220> FEATURE:
150 <221> NAME/KEY: MISC_FEATURE
151 <222> LOCATION: (7)..(7)
152 <223> OTHER INFORMATION: dimerised by formation of a disulfide bond between two Cys
153     residues in position 7 of two SEQ ID NO:7 peptides
155 <400> SEQUENCE: 7
156 Lys Pro Val Ser Leu Ser Tyr Arg Cys
157 1         5
159 <210> SEQ ID NO: 8
160 <211> LENGTH: 10
161 <212> TYPE: PRT
162 <213> ORGANISM: Artificial Sequence
164 <220> FEATURE:
165 <223> OTHER INFORMATION: portion of synthetic CXCR4 agonist SDF-1(1-9)-2
166     (Compound #3)
168 <220> FEATURE:
169 <221> NAME/KEY: MOD_RES
170 <222> LOCATION: (10)..(10)
171 <223> OTHER INFORMATION: Xaa = Lys whose epsilon amino group forms a covalent amide
172     bond with the alpha amino group of Cys at position 9 of
173     KPVSLSYRC (SEQ ID NO:9), thereby forming a dimer
175 <400> SEQUENCE: 8
W--> 176 Lys Pro Val Ser Leu Ser Tyr Arg Cys Xaa
177 1         5         10
179 <210> SEQ ID NO: 9
180 <211> LENGTH: 9

```

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:36

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

```

181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: portion of synthetic CXCR4 agonist SDF-1(1-9)-2
186     (Compound #3)
188 <220> FEATURE:
189 <221> NAME/KEY: MOD_RES
190 <222> LOCATION: (9)..(9)
191 <223> OTHER INFORMATION: Xaa = Cys whose alpha amino group forms a covalent amide
192     bond with the epsilon amino group of Lys at position 10
193     of KPVSLSYRCX (SEQ ID NO:8), thereby forming a dimer
195 <400> SEQUENCE: 9 ,
W--> 196 Lys Pro Val Ser Leu Ser Tyr Arg Xaa
197 1          5
199 <210> SEQ ID NO: 10
200 <211> LENGTH: 9
201 <212> TYPE: PRT
202 <213> ORGANISM: Artificial Sequence
204 <220> FEATURE:
205 <223> OTHER INFORMATION: portion of synthetic CXCR4 agonist dimer of SDF-1 amino
206     acids 1-8
208 <220> FEATURE:
209 <221> NAME/KEY: MOD_RES
210 <222> LOCATION: (9)..(9)
211 <223> OTHER INFORMATION: Xaa = Lys whose epsilon amino group forms a covalent amide
212     bond with the alpha amino group of Arg at position 8 of
213     KPVSLSYX (SEQ ID NO:11), thereby forming a dimer
215 <400> SEQUENCE: 10
W--> 216 Lys Pro Val Ser Leu Ser Tyr Arg Xaa
217 1          5
219 <210> SEQ ID NO: 11
220 <211> LENGTH: 8
221 <212> TYPE: PRT
222 <213> ORGANISM: Artificial Sequence
224 <220> FEATURE:
225 <223> OTHER INFORMATION: portion of synthetic CXCR4 agonist dimer of SDF-1 amino
226     acids 1-8
228 <220> FEATURE:
229 <221> NAME/KEY: MOD_RES
230 <222> LOCATION: (8)..(8)
231 <223> OTHER INFORMATION: Xaa = Arg whose alpha amino group forms a covalent amide
232     bond with the epsilon amino group of Lys at position 9
233     of KPVSLSYRX (SEQ ID NO:10), thereby forming a dimer
235 <400> SEQUENCE: 11
W--> 236 Lys Pro Val Ser Leu Ser Tyr Xaa
237 1          5
239 <210> SEQ ID NO: 12
240 <211> LENGTH: 30
241 <212> TYPE: PRT

```

RAW SEQUENCE LISTING

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:36

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

242 <213> ORGANISM: Artificial Sequence
 244 <220> FEATURE:
 245 <223> OTHER INFORMATION: synthetic CXCR4 agonist SDF-1(1-14)-(G)-3-SDF-1(55-67)
 246 acid
 248 <220> FEATURE:
 249 <221> NAME/KEY: MISC_FEATURE
 250 <222> LOCATION: (17)..(17)
 251 <223> OTHER INFORMATION: Gly in position 17 may be present or absent
 253 <400> SEQUENCE: 12
 254 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
 255 1 5 10 15
 256 Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
 257 20 25 30
 259 <210> SEQ ID NO: 13
 260 <211> LENGTH: 31
 261 <212> TYPE: PRT
 262 <213> ORGANISM: Artificial Sequence
 264 <220> FEATURE:
 265 <223> OTHER INFORMATION: synthetic CXCR4 agonist SDF-1(1-14)-(G)-4-SDF-1(55-67)
 266 acid, CTCE0013
 268 <220> FEATURE:
 269 <221> NAME/KEY: MISC_FEATURE
 270 <222> LOCATION: (17)..(18)
 271 <223> OTHER INFORMATION: Gly in positions 17 and/or 18 may independently be
 272 present or absent
 274 <400> SEQUENCE: 13
 275 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
 276 1 5 10 15
 277 Gly Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
 278 20 25 30
 280 <210> SEQ ID NO: 14
 281 <211> LENGTH: 30
 282 <212> TYPE: PRT
 283 <213> ORGANISM: Artificial Sequence
 285 <220> FEATURE:
 286 <223> OTHER INFORMATION: synthetic CXCR4 agonist SDF-1(1-14)-(G)-3-SDF-1(55-67)
 287 amide
 289 <220> FEATURE:
 290 <221> NAME/KEY: MISC_FEATURE
 291 <222> LOCATION: (17)..(17)
 292 <223> OTHER INFORMATION: Gly in position 17 may be present or absent
 294 <220> FEATURE:
 295 <221> NAME/KEY: MOD_RES
 296 <222> LOCATION: (30)..(30)
 297 <223> OTHER INFORMATION: AMIDATION
 299 <400> SEQUENCE: 14
 300 Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
 301 1 5 10 15
 302 Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/086,177C

DATE: 10/19/2006
TIME: 08:31:37

Input Set : A:\80421-1.APP
Output Set: N:\CRF4\10192006\J086177C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:8; Xaa Pos. 10
Seq#:9; Xaa Pos. 9
Seq#:10; Xaa Pos. 9
Seq#:11; Xaa Pos. 8
Seq#:31; Xaa Pos. 9
Seq#:32; Xaa Pos. 8
Seq#:35; Xaa Pos. 2,5
Seq#:36; Xaa Pos. 2,5
Seq#:39; Xaa Pos. 20
Seq#:40; Xaa Pos. 20
Seq#:41; Xaa Pos. 28
Seq#:42; Xaa Pos. 28
Seq#:43; Xaa Pos. 20
Seq#:44; Xaa Pos. 20
Seq#:45; Xaa Pos. 28
Seq#:46; Xaa Pos. 28
Seq#:50; Xaa Pos. 2,5
Seq#:51; Xaa Pos. 2,5,14
Seq#:52; Xaa Pos. 1
Seq#:53; Xaa Pos. 2,5
Seq#:54; Xaa Pos. 2,5,14
Seq#:55; Xaa Pos. 1
Seq#:58; Xaa Pos. 14
Seq#:59; Xaa Pos. 1
Seq#:61; Xaa Pos. 14
Seq#:62; Xaa Pos. 1
Seq#:64; Xaa Pos. 14
Seq#:65; Xaa Pos. 1
Seq#:68; Xaa Pos. 1
Seq#:70; Xaa Pos. 14
Seq#:71; Xaa Pos. 1
Seq#:73; Xaa Pos. 14
Seq#:74; Xaa Pos. 1
Seq#:76; Xaa Pos. 14
Seq#:77; Xaa Pos. 1
Seq#:79; Xaa Pos. 14
Seq#:80; Xaa Pos. 1
Seq#:82; Xaa Pos. 14
Seq#:83; Xaa Pos. 1
Seq#:85; Xaa Pos. 14
Seq#:86; Xaa Pos. 1
Seq#:88; Xaa Pos. 14
Seq#:89; Xaa Pos. 1
Seq#:91; Xaa Pos. 14

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/086,177C

DATE: 10/19/2006
TIME: 08:31:37

Input Set : A:\80421-1.APP
Output Set: N:\CRF4\10192006\J086177C.raw

Seq#:92; Xaa Pos. 1
Seq#:94; Xaa Pos. 14
Seq#:95; Xaa Pos. 1
Seq#:97; Xaa Pos. 14
Seq#:98; Xaa Pos. 1
Seq#:100; Xaa Pos. 14
Seq#:101; Xaa Pos. 1

VERIFICATION SUMMARY

DATE: 10/19/2006

PATENT APPLICATION: US/10/086,177C

TIME: 08:31:37

Input Set : A:\80421-1.APP

Output Set : N:\CRF4\10192006\J086177C.raw

L:176 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:196 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:216 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:236 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31 after pos.:0
L:767 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32 after pos.:0
L:773 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (33) SEQUENCE:
L:778 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (34) SEQUENCE:
L:824 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35 after pos.:0
L:873 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36 after pos.:0
L:966 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39 after pos.:16
L:1003 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:16
L:1035 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41 after pos.:16
L:1072 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:42 after pos.:16
L:1104 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:43 after pos.:16
L:1141 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44 after pos.:16
L:1173 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45 after pos.:16
L:1210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46 after pos.:16
L:1341 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50 after pos.:0
L:1382 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51 after pos.:0
L:1413 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:52 after pos.:0
L:1460 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53 after pos.:0
L:1501 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:54 after pos.:0
L:1532 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55 after pos.:0
L:1605 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:58 after pos.:0
L:1635 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:0
L:1689 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61 after pos.:0
L:1719 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62 after pos.:0
L:1763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64 after pos.:0
L:1793 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65 after pos.:0
L:1882 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68 after pos.:0
L:1926 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70 after pos.:0
L:1956 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71 after pos.:0
L:2010 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:73 after pos.:0
L:2040 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:74 after pos.:0
L:2084 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76 after pos.:0
L:2114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77 after pos.:0
L:2168 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79 after pos.:0
L:2198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80 after pos.:0
L:2242 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:82 after pos.:0
L:2272 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:83 after pos.:0
L:2326 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:85 after pos.:0
L:2356 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86 after pos.:0
L:2400 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:88 after pos.:0
L:2430 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:89 after pos.:0
L:2484 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:91 after pos.:0
L:2514 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:92 after pos.:0
L:2558 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:94 after pos.:0

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/086,177C

DATE: 10/19/2006

TIME: 08:31:37

Input Set : A:\80421-1.APP

Output Set: N:\CRF4\10192006\J086177C.raw

L:2588 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:95 after pos.:0
L:2642 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:97 after pos.:0
L:2672 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:98 after pos.:0
L:2716 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:100 after pos.:0